Authored By: Sarah
23 Aug 2024

Breast Cancer Monoclonal Antibodies Market Size to grow by USD 19.2 billion between 2024-2028

Technavio, a leading provider of market research reports, has released its latest study on Breast Cancer Monoclonal Antibodies Market. This report offers a comprehensive analysis of the current market trends, emerging opportunities, and key challenges.

Key Highlights:

  • Market Research Overview: The global pharmaceuticals market encompasses entities involved in the research and development (R&D) or production of various drug categories, including generics, non-generics, and veterinary drugs. According to Technavio, the healthcare market size is determined by the collective revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the pharmaceuticals sector include the increasing global population aging, with the proportion of individuals above 60 years projected to rise significantly. By 2050, approximately one-quarter of the US population and Europe's population ratio is expected to reach this demographic milestone. - The Breast Cancer Monoclonal Antibodies Market is experiencing significant growth, fueled by the Increasing prevalence of breast cancer. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

  • Major Findings:
    • Increasing prevalence of breast cancer
    • Rising number of patient support initiatives for breast cancer awareness
    • High cost of breast cancer monoclonal antibody treatment when compared to traditional therapies
    • Side effects and safety concerns associated with breast cancer monoclonal antibody treatment
  • Growth Projections

The market size is estimated to grow by USD 19.2 billion, at a CAGR of 13.97% during the forecast period. The Breast Cancer Monoclonal Antibodies market is poised for significant growth as an increasing number of these treatments receive regulatory approval. This expanding portfolio of options caters to the demand for effective and targeted therapies. Notably, Merck's pembrolizumab (Keytruda) was approved by the US FDA in July 2021 for neoadjuvant and adjuvant treatment of high-risk, early-stage Triple-Negative Breast Cancer (TNBC), marking a significant addition to the market. Furthermore, a robust product pipeline indicates ongoing research and development efforts, promising the introduction of innovative therapies.

For insights on company offerings- Request a sample report!

  • Regional Insights

The Breast Cancer Monoclonal Antibodies market represents a significant business opportunity due to the increasing prevalence of breast cancer and the growing demand for targeted therapies. Monoclonal antibodies, as precision oncology tools, offer effective treatment options by specifically targeting cancer cells. Key market players are investing in research and development to launch novel monoclonal antibodies and expand their product portfolios, thereby driving market growth.

About Technavio                                                                        

Technavio is a global market research company offering comprehensive reports and insights on various industries. Our research helps businesses make informed decisions by providing actionable data and trends. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions. Technavio is one of the most influential market research and advisory firms in the world. We work with business and technology leaders to provide cutting-edge market research and insights to companies. 

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio